The aim of this study was to explore cost and health consequences of using drug eluting stents (DES) instead of bare metal stents (BMS) for patients with stable angina.
PCV6

IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE MORTALITY FOLLOWING CARDIOVASCULAR HOSPITALIZATION IN A MANAGED CARE POPULATION
. METHODS: An integrated US medical/pharmacy claims database (43 million members) was used to examine patient mortality risk following hospitalization discharge for CVEP (nonfatal MI, resuscitated cardiac arrest, acute coronary occlusion, CABG or PTCA). Inclusion criteria: age 18 years, health plan enrollment >12 months prior to and >1 month after hospitalization, and index hospitalization for CVEP between January 2000 to June 2003. Patients were identified as receiving no statin therapy within 30 days after discharge (S-), or receiving statin therapy. Statin therapy was defined as standard (STD) or intensive (INT), < or >40% LDL-C lowering efficacy according to the package insert. Patients were matched (INT vs. S-, STD vs. S-, and INT vs. STD) based on estimated propensity scores for statin therapy to adjust for baseline differences. Death was presumed from claims activity indicating a likely fatal event followed by health plan disenrollment. Mortality was compared among groups using Cox proportional hazards models controlling for prognostic factors. 
PCV7 COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE DISEASE IN POLAND
Glinka M, Kowalik E, Wlodarska EK, Wozniak O, Hoffman P Institute of Cardiology, Warsaw, Poland OBJECTIVES: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined heart muscle disease associated with arrhythmia, heart failure and sudden death often being the first manifestation in probands. The aim of the study was to evaluate the costs of diagnosis of the disease in asymptomatic relatives in Poland. METHODS: A total of 239 asymptomatic subjects (mean age 35 yeas, 120 men) belonging to 42 families affected with ARVC were examined between May 2003 and May 2005. The costs of out-patients visit and additional diagnostic tests were included. Payer perspective was used. RESULTS: In all individuals electrocardiogram and transthoracic echocardiography were performed. Magnetic resonance imaging and signal averaged electrocardiogram were performed in 35 patients suspected of having ARVC. The diagnostic criteria for ARVC were detected in 29 patients and 57 subjects fulfilled the borderline criteria for ARVC. Total costs of screening amounted to €13,086.35. The average cost per one case of ARVC detected was €451.25. CONCLUSIONS: Costs of early detection of ARVC in individuals with a family history of the disease are low and enable the family screening in asymptomatic subjects in Poland.
PCV8 COST OF HOSPITALIZATION FOR PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND
Kowalik E, Glinka M, Wlodarska EK, Wozniak O, Hoffman P Institute of Cardiology, Warsaw, Poland OBJECTIVES: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a progressive heart muscle disease characterized by replacement of right ventricular myocardium by fibrofatty tissue and resulting in life threatening ventricular arrhythmias and heart failure. The aim of the study was to evaluate costs of hospital care in cardiology department for patients with ARVC in Poland. METHODS: Data on resource utilization were collected prospectively in patients with ARVC hospitalized in the tertiary center from May 2003 to May 2005. Patients' stay fixed costs, costs of additional tests and procedures were extracted from hospital sources. Payer perspective was used. RESULTS: A group of 39 patients with mean age 41.4 years (56% male) was analyzed. Average length of stay in the cardiologic department was 13.4 days (ranging from 2 to 76 days). Total costs of hospital care amounted to €191,029.90. Average cost per patient was €4898.20. Procedural costs represented the major cost item
